Epidermal Growth Factor As a biomarker for early detection of Hepatocellular Carcinoma

Document Type : Original Article

Authors

1 Internal Medicine, Faculty of Medicine, Al-Azhar University

2 Departments of 1Internal Medicine,Faculty of Medicine, Al-Azhar University, Egypt

3 Clinical Pathology and Laboratory, Faculty of Medicine, Al-Azhar University, Egypt

Abstract

Background: Hepatocellular carcinoma (HCC) is the sixth greatest frequent disease in the world and the second biggest cause of cancer mortality in men in developing nations, with over 782,000 deaths globally each year, with China accounting for almost half of them.
Aim of the study: The goal of this research was to see whether epidermal growth factor might be used as an indicator for early detection of hepatocellular cancer.
Patients and methods: One hundred patients were selected from the Internal Medicine department's outpatient clinic and ward at Sayed Galal University Hospital for this case control research. The study's patients were placed into three groups: Group I : 40 patients with HCC, Group II : 40 cirrhotic patients without HCC, and Group III : 20 healthy people who were devoid of hepatic diseases stigmata.
Results: Sensitivity, specificity and accuracy of AFP in differentiate between HCC and cirrhosis. Sensitivity was (92%), specificity (90%) and accuracy (91%) with cut off value 5.8. Sensitivity, specificity and accuracy of H. EGF in differentiate between HCC and cirrhosis. Sensitivity was (99%), specificity (100%) and accuracy (99%) with cut off value 350. There was statistically substantial connection between AFP, H. EGF and other laboratory findings (P < 0.05).
Conclusion: In the detection of early HCC, epidermal growth factor as an indicator is a helpful biomarker that might supplement the effectiveness of AFP.

Keywords

References

  1. Yang C, Wang YL, Sun D, Zhu XL, Li Z, et al. Increased expression of epidermal growth factor-like domain containing protein 7 is predictive of poor prognosis in patients with hepatocellular carcinoma. J Can Res Ther. 2018; 14: 867-72.
  2. El-Sergany HF, Mohamed AM, Madkour NK, El-Sebeaey MA, Fared AM, et al. Epidermal Growth Factor Gene Polymorphism in Egyptian Patients with Hepatocellular carcinoma related to Hepatitis C. J Gastroenterol Hepatol Res. 2017; 6(6): 2481-5
  3. Zakhary N, El-Merzabani M, El-Sawi N, Saleh M, Moneer M, et al. Impact of different biochemical markers in serum of patients with benign and malignant liver diseases. J Adv Res. 2011; 2(1): 49-55.
  4. Kohla MAS, Al-Haddad OK, Nada A, AlWarraky M, Obada M, et al. Association of serum levels of epidermal growth factor with disease severity in patients with unresectable hepatocellular carcinoma. Hepatoma Res. 2016; 2: 18-25.

 

  1. Mohamed AA, Drees EA, Abdelmoneim AM, Mohmoud S, Shalaby H, et al. Evaluation of Human Epidermal Growth Factor as a Tumor Marker in Patients with Hepatocellular Carcinoma Related to Hepatitis C Virus. Adv Res Gastroenterol Hepatol. 2016; 1(3): 555565.
  2. Zona L, Lupberger J, Sidahmed-Adrar N, Thumann C, Harris HJ, et al. HRAs signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe. 2013; 13: 302–13.
  3. Baghdady I, Fouad F, Sayed M, Shoaib A, Salah Y, et al. Serum markers for the early detection of hepatocellular carcinoma in patients with chronic viral hepatitis C infection. Menoufia Medical Journal. 2014; 27(3): 544.‏
  4. Durazo FA, Blatt LM, Corey WG. Des-gamma-carboxy-prothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol. 2008; 23:1541–8.
  5. Lopez-Luque J, Caballero-Diaz D, Martinez-Palacian A, Roncero C, Moreno-Caceres J, Garcia-Bravo M, et al. Dissecting the role of the epidermal growth factor receptor catalytic activity during liver regeneration and hepatocarcinogenesis. Hepatology. 2016; 63: 604-19.
  6. Okonkwo UC, Nwosu MN, Nnadozie OJ. Is liver function test of any diagnostic relevance in patients presenting with hepatocellular carcinoma?. Orient J Med. 2011; 23:1–4.

 

  1. Abd-Elfatah S, Khalil F. Evaluation of the role of alpha-fetoprotein (AFP) levels in chronic viral hepatitis C patients, without hepatocellular carcinoma (HCC). AAMJ, 2014; 12(1): 31-7.‏
  2. Jasirwan COM, Fahira A, Siregar L, Loho I. The alpha-fetoprotein serum is still reliable as a biomarker for the surveillance of hepatocellular carcinoma in Indonesia. BMC Gastroenterology. 2020; 20(1): 1-8.‏
  3. Shehata F, Abdel Monem N, Sakr M, Kasem S, Balbaa M. Epidermal growth factor, its receptor and transforming growth factor-β1 in the diagnosis of HCV-induced hepatocellular carcinoma. Medical Oncology. 2013; 30(3): 1-7.‏
  4. Berasain C, Latasa MU, Urtasun R, Gon˜i S, Elizalde M, et al. Epidermal growth factor receptor (EGFR) crosstalks in liver cancer. Cancers. 2011; 3:2444–61.
  5. Buckley AF, Burgart LJ, Sahai V, Kakar S. Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol. 2008; 129: 245–51.
  6. Dong ZZ, Yao DF, Yao M, Qiu LW, Zong L, et al. Clinical impact of plasma TGF-beta1 and circulating TGF-beta1 mRNA in diagnosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2008; 7:288–95.
  7. Shirai Y, Kawata S, Tamura S, Ito N, Tsushima H, et al. Plasma transforming growth factor-b in patients with hepatocellular carcinoma: comparison with chronic liver disease. Cancer. 1994; 73: 2275–9.

 

Files

Share

How to cite

Statistics